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ABSTRACT
Objectives: To develop a nurse-led, urologist-
supported model of care for men managed by active
surveillance or active monitoring (AS/AM) for localised
prostate cancer and provide a formative evaluation of
its acceptability to patients, clinicians and nurses.
Nurse-led care, comprising an explicit nurse-led
protocol with support from urologists, was developed
as part of the AM arm of the Prostate testing for
cancer and Treatment (ProtecT) trial.
Design: Interviews and questionnaire surveys of
clinicians, nurses and patients assessed acceptability.
Setting: Nurse-led clinics were established in 9
centres in the ProtecT trial and compared with 3 non-
ProtecT urology centres elsewhere in UK.
Participants: Within ProtecT, 22 men receiving AM
nurse-led care were interviewed about experiences of
care; 11 urologists and 23 research nurses delivering
ProtecT trial care completed a questionnaire about its
acceptability; 20 men managed in urology clinics
elsewhere in the UK were interviewed about models of
AS/AM care; 12 urologists and three specialist nurses
working in these clinics were also interviewed about
management of AS/AM.
Results: Nurse-led care was commended by ProtecT
trial participants, who valued the flexibility, accessibility
and continuity of the service and felt confident about
the quality of care. ProtecT consultant urologists and
nurses also rated it highly, identifying continuity of
care and resource savings as key attributes. Clinicians
and patients outside the ProtecT trial believed that
nurse-led care could relieve pressure on urology clinics
without compromising patient care.
Conclusions: The ProtecT AM nurse-led model of
care was acceptable to men with localised prostate
cancer and clinical specialists in urology. The protocol
is available for implementation; we aim to evaluate its
impact on routine clinical practice.
Trial registration numbers: NCT02044172;
ISRCTN20141297.
INTRODUCTION
Prostate cancer (PCa) is the most common
cancer in men in the UK, making up 26% of
male cancer diagnoses in England and Wales
in 2010.1 The 2010 UK PCa prevalence was
estimated at over 250 000 with the possibility
of a threefold increase or more by 2040.2
Given the indolent nature of many of these
cancers and the risks of side effects asso-
ciated with current radical treatments,3
various non-radical approaches have been
developed for men diagnosed with localised
disease.4 5
Active surveillance (AS) and active moni-
toring (AM) programmes aim to offer men
the option of avoiding immediate surgery or
Strengths and limitations of this study
▪ The strengths of this study include that it was
embedded in the Prostate testing for cancer and
Treatment (ProtecT) randomised controlled trial
of treatments for localised prostate cancer, pro-
viding a framework for the development of a
model of nurse-led active monitoring/active sur-
veillance care and enabling the training of nurses
alongside clinicians.
▪ It was supplemented by data from another large
nationally funded study that enabled views on
nurse-led active monitoring/active surveillance
care for men with localised prostate cancer from
outside the ProtecT trial to be accessed.
▪ The model of care has been clearly outlined and
is ready to be evaluated.
▪ The limitations of the study are that the model
has been presented and evaluated descriptively;
it has not yet been fully evaluated for its cost-
effectiveness or impact on routine practice.
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radiotherapy (RT; and their adverse events) with disease
monitoring, so that those whose disease remains stable
can avoid intervention and those whose disease pro-
gresses can have curative treatment. Programmes have
developed with variable eligibility criteria, management
protocols and triggers for clinical review and change of
management.6 AS was developed originally in North
America7 and is now recommended in European8 and
US9 guidelines. UK National Institute for Health and
Care Excellence (NICE) guidelines recommend that AS
be offered to men suitable for radical treatments and
with low-risk localised PCa (deﬁned as prostate-speciﬁc
antigen (PSA) ≤10 ng/mL and Gleason ≤6 and stage
T1-T2a disease); and considered for men with
intermediate-risk localised PCa (deﬁned as low risk but
with one or more of: PSA=10–20 ng/mL or Gleason 7 or
T2b disease).1 Monitoring in AS programmes tends to
include scheduled repeat prostate biopsies as well as
regular PSA testing and digital rectal examination
(DRE).1 The AM protocol for the Prostate testing for
cancer and Treatment (ProtecT) trial included men
with low-risk and intermediate-risk PCa and employed a
particular form of regular PSA monitoring (see below).
It differed from AS programmes primarily as prostate
biopsies were not part of regular scheduled monitoring
but could be used as part of the clinical assessment of
disease progression.10
Once on AS/AM, men need regular monitoring.
Although UK NICE guidelines allow for PSA testing to
take place in primary care and for DRE to be carried
out by a suitably qualiﬁed health professional,1 monitor-
ing is usually led by urologists, which results in increased
demands on urology services, ﬁlling clinics with routine
management and infrequent interventions rather than
expert care.11 Alternatives to standard consultant-led
outpatient clinics include clinics led by specialist nurses.
Features that distinguish nurse-led clinics include the
nurse having their own patient caseload, an increase in
autonomy of the nursing role, and the ability to admit
and discharge patients from the clinic or to refer to
other clinical colleagues.12 Nurse-led management is
well established in cancer care,13 including post-
treatment follow-up in urological oncology,14–17 and
shared care, integrated services between primary and
secondary care.18 However, nurse-led clinics for routine
monitoring postdiagnosis are not yet common.
Description of nurse-led ProtecT AM
The aim of nurse-led ProtecT AM was to ensure that
consistent delivery of routine activity was achieved by
nurses, with rapid provision of consultant urologist
advice and support when required. The protocol for
nurse-led ProtecT AM therefore included guidelines for
nurses and established clear lines of communication
between the nurses and principal study urologist.10
There were four core components: (1) the treatment
pathway that deﬁned the type and timing of tests, signiﬁ-
cance of test results and actions required; (2) quality
assurance processes, including standard operating proce-
dures (SOPs), training, meetings and site monitoring;19
(3) development of integrated working with primary
care for PSA testing and (4) feedback from patients
regarding timing, frequency and location of clinics. All
four core components were incorporated in nurse-led
clinics.
The ProtecT AM protocol involved regular PSA tests
with referral to the urologist for additional tests (eg, pros-
tate biopsy, bone/MRI) if there were indications of pro-
gression or other clinical concerns. At the time of each
PSA test, the most recent PSA result was compared with
previous results and in particular results taken 12 months
previously. Patient-reported physical problems, in particu-
lar lower urinary tract symptoms and psychological con-
cerns, were also considered. Whenever possible, PSA
testing was performed in primary care, 2–3 weeks prior
to the clinic appointment date, allowing time for a
nurse-led preclinic review of patient history and current
status and additional tests as necessary. Careful tracking
and coordination of appointments, using a database with
built-in alerts, helped ensure optimum efﬁciency, par-
ticularly with regard to face-to-face appointments.
AM appointments were conducted by research nurses
all of whom underwent initial and ongoing local and
national training, including one-to-one assessment of
practice within the trial. Communication within the
nursing team was shared, so that each nurse was able to
provide planned and short-notice cover. All nurses had
direct access to the principal study urologist and other
designated urologists and oncologists to ensure timely,
expert advice. Documented permission for nurses to
deliver treatment was ofﬁcially delegated by the princi-
pal urologist following review and approval of the RCT
by the host National Health Service (NHS) trust.
Patients had direct access to the ProtecT trial AM team
by telephone (24/7 answerphone available) or by email.
The location of face-to-face appointments in either
primary or secondary care took account of patients’
wishes, availability of staff and the level of expertise
required for any given appointment. Telephone appoint-
ments were conducted when a face-to-face appointment
was not required, for example, interim PSA test results.
This paper presents the model of nurse-led AM that
was developed within the ProtecT randomised controlled
trial (RCT) of treatments for men with clinically loca-
lised PCa. A formative evaluation of its acceptability to
patients, clinicians and nurses within and outside the
trial suggests that it could be implemented more widely
to reduce pressure on increasingly overstretched uro-
logical services.
METHODS
The ProtecT study
The ProtecT RCT involved a programme of PSA testing
among men in the community aged 50–69 years in nine
trial centres.10 Participants diagnosed with clinically
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localised PCa (T1-T2, PSA 3.0–19.99 ng/mL, Gleason
6 or 7) were offered randomisation to AM, three-
dimensional conformal external beam radical RT or
radical prostatectomy. ProtecT trial centres were led by a
consultant urologist and a senior research nurse. In
total, 545 men were randomised to AM; in addition 529
refused randomisation and chose AM.10 All patients
were followed up with the same protocol.
A nested trial during the feasibility phase of the trial
showed that nurses were as effective, and more cost-
effective than doctors for recruitment.20 Nurse-led
clinics and follow-up procedures were developed, like-
wise led by trained research nurses, with the aim of
ensuring high levels of protocol adherence, data quality
and minimising loss to follow-up.10
The protocol for the AM pathway was developed for
the trial based on available evidence.21 Scheduled
rebiopsy was not included, and disease review was based
on a conﬁrmed 50% rise in PSA level over the previous
12-month period.10 As the trial progressed, the protocol
was reviewed by the international Trial Steering
Committee (TSC) to ensure continued relevance, and
SOPs were developed and discussed regularly at meet-
ings and training events. All amendments to the proto-
col received ethics committee approval.
Over 1000 men in nine clinical centres across the UK
received ProtecT nurse-led AM, including those ran-
domly allocated to AM and those who chose AM having
declined randomisation. Recruitment to the ProtecT
main trial started in 2001 and ended in 2009.10
Evaluating the acceptability of nurse-led ProtecT AM
Participants and methods
The aim of this study was to assess the acceptability of
ProtecT nurse-led AM to men, urologists and research
nurses within the ProtecT trial, and to compare these
with experiences of standard urologist-led AS care in
urology centres outside the ProtecT trial. The study
combined in-depth interviews and questionnaire surveys.
Patients. As part of a larger ProtecT qualitative study,
24 men randomised to or choosing ProtecT AM in four
clinical centres were invited for interview. Purposive sam-
pling was used to include men across the age and socio-
economic range with low-risk and intermediate-risk
localised PCa at diagnosis (Gleason score 6 or 7 and
PSA ≤19.99 ng/mL) who had undergone AM for at least
6 months. These men were informed of the interview
study by letter and patient information leaﬂet, followed
by a telephone call by JW 2 weeks later, unless men had
indicated refusal using a written reply. Interviews were
conducted by JW or CES (credentials in online supple-
mentary appendix C), during which views on nurse-led
AM were explored. In a related study exploring
urologist-led AS practice in three centres not involved in
the ProtecT trial,22 purposive sampling was used to iden-
tify men across the age and socioeconomic range with
low-risk localised PCa at diagnosis (Gleason score 6 and
PSA ≤10 ng/mL) who had undergone AS for at least
12 months and were judged by their clinician to show
no evidence of disease progression. Twenty men were
given or sent a recruitment information pack which
asked them to contact LR if they wished to participate in
an interview with LR or JW about their views of AS.
Health professionals: All 12 urologists and 3 clinical
nurse specialists (CNSs) delivering consultant-led AS in
three clinics not involved in the ProtecT trial were
invited for interview with LR or JW to discuss their views
about AS.22 All 11 urologists and 23 research nurses cur-
rently working in the ProtecT trial were invited to com-
plete questionnaires about their experiences of
delivering nurse-led AM.
Twenty-two of the 24 invited men took part in inter-
views investigating experiences of nurse-led AM within
the ProtecT trial (AM1–AM22, table 1, two declined
participation without stating the reason). All 20 invited
men receiving AS outside the ProtecT trial consented
to participate in single interviews of their experiences
(AS1–AS20, table 1). Some men chose to be interviewed
with their wife or partner present, in which case these
were subject to the same consent procedures. All 12
urologists (U1–U12) and all 3 CNSs (CNS1–CNS3)
invited to single interviews of their experience of
urologist-led AS outside the ProtecT trial agreed to par-
ticipate. No interviewees were previously known to their
interviewer. All participants were informed of their
interviewer’s occupation, employer and the purpose of
the interview.
Data collection
Interviews were semistructured using a topic guide
(ﬁgure 1) to elicit interviewees’ experiences of AS/AM
and reﬂections on how procedures could be improved,
while allowing interviewees to raise issues of importance
to them. Interviews were face-to-face or by telephone in
Table 1 Characteristics of men participating in the
in-depth interview study
Men receiving
AM within
ProtecT (N=22)
Men
receiving
AS (N=20)
Age at time of first interview:
mean (range)
64;7
(53;11–70;10)
65 (55–70)
Ethnicity, N (%)
White 21 20 (100)
Other 1 0 (0)
Treatment decision-making
Accepted randomly
allocated treatment
12 NA
Chose treatment 10 20
Interview type*
Telephone 33 0
Face-to-face 40 20
*Some men in ProtecT gave several interviews.
AM, active monitoring; AS, active surveillance; NA, not available;
ProtecT, Prostate testing for cancer and Treatment.
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each interviewee’s preferred location (eg, home or clinic
room in urology centres) and ranged from 8 min
(ProtecT patient, third interview) to 1 h and 36 min
(patients), with most lasting between 30 and 60 min;
and from 20 min to 1 hs and 5 min (health profes-
sionals). Findings from patient and health professional
interviews were used to develop urologist (see online
supplementary appendix A) and nurse (see online
supplementary appendix B) questionnaires. These were
completed anonymously and returned via a clerical
ofﬁcer to maintain conﬁdentiality. A reminder was sent
after 4 weeks to request completion and return of the
questionnaire.
Qualitative data analysis
Interviews were audio-recorded, transcribed verbatim
and transcripts supplemented by accompanying ﬁeld
notes. Transcripts were scrutinised to identify recurrent
themes emerging from the data. Transcripts were ana-
lysed in groups (eg, men receiving nurse-led vs
urologist-led care, urologists vs specialist nurses, by study
centre) to identify commonalities and contrasts between
groups or individuals. The interview topic guides for
each qualitative study were reﬁned during the interview
process as themes emerged, in accordance with princi-
ples of constant comparison methods derived from
grounded theory.23 24 Data collection and analysis pro-
ceeded in tandem, with sampling continuing until the
point of data saturation. Analysis was facilitated by use of
qualitative computer software NVivo,25 and led by JW,
with a subset of 32 interviews also analysed by LR.
Findings were discussed and synthesised to maximise
reliability of coding and data interpretation.23
Questionnaire data analysis
Questions were presented using a mixture of dichotom-
ous ‘yes’ or ‘no’ responses, a ﬁve-point Likert scale
(ranging from ‘strongly agree’ to ‘strongly disagree’),
tick boxes for named activity and free text boxes.
Descriptive analyses were undertaken because of the
small number of participants in each survey. Free text
comments were analysed using thematic analysis.23
RESULTS
Interview study
The majority of participants in the ProtecT trial
reported satisfaction with nurse-led AM. Three key
themes emerged in support of nurse-led care: (1) efﬁ-
cient use of resources, (2) quality of care and (3) con-
venience of care. A majority of men receiving
consultant-led AS (N=12) and a majority of clinicians or
nurses involved in delivering AS outside the ProtecT
trial (N=9) supported alternatives to the consultant-led
model, citing the reasons above and also suggesting that
(4) nurse-led care was a natural extension of existing
nurse practice. A small number of concerns were raised
about nurse-led care (5), but suggestions were made for
key components of care (6) that would minimise risks
when moving to a nurse-led model.
Several ProtecT trial participants were interviewed
more than once therefore interview number and timing
postdiagnosis is given following each quote, for example,
AM1/2, 2 years 3 months denotes second interview with
participant AM1, 2 years, 3 months postdiagnosis.
Efficient use of resources
Men receiving both nurse-led and consultant-led care
argued that nurses could provide more cost-effective
care than consultants:
Why bring him [urologist] in at enormous expense when
he’s far better cutting people up and sorting them out?
(AM6/2, 2 years 1 month)
I’m very concerned about the cost to the NHS. Anything
that reduces the cost of the NHS I’d be happy about.
And if it frees up a consultant, or whatever, to do some-
thing else. (AS12)
Urologists and CNSs delivering consultant-led AS
agreed that most appointments were routine and could
be safely delegated to CNSs to maximise efﬁciency in
the face of growing numbers of men on AS/AM:
We’re just getting inundated by people, and there’s a
limit to the number of consultants that the hospital and
the country can afford. (U9)
It’s something that can be quite clearly protocolised and
be run safely by a clinical nurse specialist. (CNS1)
Quality of care
Men receiving nurse-led AM reported high levels of con-
ﬁdence in the quality of care delivered by nurses. This
conﬁdence developed over time and was attributed to
how nurses responded to concerns or queries:
Initially I was a bit concerned about it to be honest with
you. As I say, initially—we’re talking 2008 now—I was
seeing a nurse rather than a urologist. But over the time
and especially with [NURSE NAME] I began to believe
that they have such a base of knowledge that I have
Figure 1 Topics covered in in-depth interviews (AM, active
monitoring; AS, active surveillance).
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conﬁdence in what they are saying. (AM3/3 5 years
11 months)
These men reported that nurses (1) gave men enough
time to talk through concerns, (2) were easy to contact,
(3) dealt promptly and reassuringly with concerns, (4)
were knowledgeable and experienced and (5) worked
effectively as a team with other team members, in par-
ticular arranging further investigations or consultations
with urologists as required:
I think it’s just very caring, understanding, knowledge-
able, you know, half an hour each time I go. (AM8/2,
2 years 1 month)
They do just ask how do you feel and whether it’s giving
you any trouble. When I do go over to [HOSPITAL
NAME] if I am a little worried and I do talk to them,
they put me at my ease. (AM12/2, 2 years 2 months)
I ﬁnd the whole thing so far very helpful and very
reassuring. I can’t highlight anything where they have
been unhelpful, I have never left thinking ‘I wish I had
known more a bit more about this or that…I had a full
body scan and thank goodness that proved to be no
problem and no cause for concern. So again, I have got
the conﬁdence that if I can explain that I am having a
problem in one respect or another, she [RESEARCH
NURSE] will do her best to get it sorted. (AM3/3, 6 years
0 months)
Men needing to see a consultant for review explained
further beneﬁts:
It’s nice to have the nurse there [during consultation
with urologist] perhaps so you can defer the decision
and have a private conversation with the nurse as it were
afterwards…perhaps you don’t think of the questions
while you’re in and the questions form in the back of
your mind which you wished you had asked. (AM9/2,
2 years 2 months)
It’s this lack of consistency [under consultant-led care];
you don’t see the same person. (AS6)
I think if you’re a patient yourself you would always want
to see the same person, because you feel that you build
up a rapport with them. (CNS1)
Nurse-led care was perceived as potentially more
holistic:
I think it was interesting that it [ProtecT] was a nurse-led
study…consultants can be very focused on your speciﬁc
condition and what they can do for that and I think that
a nurse can be much more holistic. (AM18/1 6 years
7 months)
I think also we’re very good, as CNSs, at giving out the
information of living with the disease, eating well,
keeping ﬁt, keeping active and all—I think they’d get a
more holistic service if it was done by the CNSs. (CNS1)
Convenience of care
Men receiving ProtecT AM valued the convenience of
deciding where their PSA blood test was taken, how they
received their result and how frequently PSA tests were
conducted. They had PSA tests at their general practi-
tioner (GP) practice (N=15), urology centre (N=6) or
during home visits by a community matron caring for a
partner (N=1). Some received results from ProtecT
nurses during face-to-face appointments in urology
centres or by telephone; others attended their GP prac-
tice and contacted practice staff for results. Men chose
the option to suit them best:
As long as I’m happy to do the phone thing then that’s
ﬁne, it suits me. Its 20 miles isn’t it, it’s not an easy place
to get into town in the morning, for 9 o’clock or half
past 9. It’s better now because the car parking is a bit
better than it was but initially it was a bit of a pain
because I needed somewhere to park up. Yeah, so it’s
once a year going down and that’s ﬁne. (AM7/3, 4 years
9 months)
Men receiving urologist-led AS (12/20) suggested that
alternatives to regular urologist-led review (such as by
telephone or Skype) would offer more convenient care.
Men receiving both models of care reported reluctance
to travel to urology centres because of lost time, travel
and parking costs. Such costs were difﬁcult to justify if
an appointment was brief, routine and involved no phys-
ical examination:
It cost me nearly four quid for a ﬁve minute appointment
when I actually got in there. (AS2)
Partner There were one or two appointments that we
came to where we thought, ‘Well’ ‘Could have done that
over the phone’. (AS11)
Even those who explicitly valued urologist-led care felt
face-to-face contact could be reduced for mutual
beneﬁt:
I think it’s quite good to see the people who may ultim-
ately operate on you or whatever happens to be the case,
and have that dialogue with them[…] and they [men]
would only come in if they [urologists] were concerned
about the velocity or whatever happened to be the case.
(AS9)
Extension of current practice
Urologists outside the ProtecT trial reported a desire to
set up nurse-led clinics, and some already had specialist
nurses who could take on such a role:
One of the things that we are looking at doing, as our
CNS numbers have now improved, is to set up a nurse-led
clinic for men on AS…All the patients that have radical
prostatectomies or brachytherapy, they’re seen in the
nurse-led clinic, and they don’t see the consultants, and
they report very high levels of satisfaction. (CNS1)
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I think there is a bit of sharing. I’ve trained a specialist
nurse to see these patients and she runs with that guide-
line that we’ve mentioned. I trained her to do rectal
examinations and to use an online calculator for doub-
ling time. And she tends to do the clinics when I’m
doing other clinics so she can pop in and ask advice if
necessary. (U11).
Concerns about nurse-led care
Some concerns were voiced about nurse-led care. All
men perceived urologists to be the overall experts and
believed key decisions should be made in consultation
with them:
I would probably have been more reassured if
(CONSULTANT NAME) could have seen me…I mean if
he had my case notes in front of him and he said ‘Look I
don’t think it is opportune at the moment to do any
operations’ I would feel more reassured…yeah that
would be more helpful to me…I think at some stage I
would probably like to say, ‘Let me have a word with
(CONSULTANT NAME)’ you know? ‘Let me see the top
honcho here and see what he says about it all’. (AM6/2
5 years 0 months)
Some men receiving urologist-led care (N=3/20)
argued that, for this reason, care exclusively by the
urologist was preferable:
You want to be in the business of talking to the people
who’d be doing the business [surgery] on you if it comes
to the crunch. (AS9)
In contrast, the two men receiving nurse-led care
(AM3 and AM6) who expressed similar initial concerns
about receiving nurse-led care as opposed to
consultant-led care reported these had dissipated
entirely by the time of their third interview (5–6 years
postdiagnosis).
Three negative experiences of nurse-led care
emerged. Two men receiving nurse-led care reported
receiving conﬂicting advice about the need to switch to
radical treatment, and another believed a nurse over-
reacted to a single rise in PSA levels by suggesting a
switch to radical treatment, whereas the urologist subse-
quently reassured him there was no such need. A spe-
cialist nurse likewise suggested nurses might be more
cautious:
It was confusing. Nobody was saying ‘yeah’ and well it was
half and half like you know and getting mixed vibes. That
was the only thing that I found wrong with it all (AM4/3,
5 years 6 months)
So the difference between nurse specialist follow-up and
consultant follow-up is that the nurse specialist will prob-
ably be more cautious. (CNS2)
Such reactions might be expected when following a
protocol and would need to be balanced with good
team working.
Key components of nurse-led care
Men receiving both models of care and urologists/CNSs
identiﬁed a number of essential components for success-
ful nurse-led care. All stated that nurse-led AS must be
explicitly protocol-driven, with frequency of routine PSA
tests, routine DRE or routine rebiopsy clearly deﬁned
and clear guidelines in place to determine when men
should be referred to urologists for consultation or
further investigation:
That’s one of the things that we’d have to iron out as a
department, is exactly the protocol for repeat digital
rectal examinations. (CNS2).
It’s good to get things into protocol driven things…So we
could trust our nurse specialists to, you know, tell us if
they fall outside. (U9)
Effective communication between nurses and urolo-
gists was essential and patients believed endorsement of
the CNS’ skills by the urologist was also important:
I’m aware that [NURSE NAME] has built a good rapport
with the consultants, so therefore we’re getting the best
people… AM9/3
Men wanted reassurance that delegation of routine
PSA blood tests to nurses should be conditional on
nurses working under direction of the urologist, with
rapid pathways for referral when required:
I still want the idea that the person can refer you…to the
consultant, should they feel it necessary. AS12
Questionnaire survey in the ProtecT trial
All 11 urologists and 23 research nurses surveyed in the
ProtecT trial completed and returned the questionnaire
(100% response rate). Urologists and nurses all agreed
(100% of nurses and 51% of urologists strongly agreed)
that the AM clinics provided beneﬁts to patients includ-
ing psychological support, continuity of care, ﬂexibility
of appointments, good quality of care and reduced the
burden on the NHS. Almost all urologists (N=9) and
nurses (N=19) agreed that AM allowed nurses to refer
concerns to relevant clinicians, and most urologists
(N=8) and nurses (N=18) believed AM clinics gave
nurses the opportunity to initiate appropriate diagnostic
tests. All urologists agreed that nurse-led AM clinics pro-
vided reliable and timely appointments for the partici-
pants, with seven believing they were likely to be
cost-effective. Just over half the urologists (N=6) carried
out or arranged routine diagnostic tests themselves. All
nurses felt they had acquired specialist skills as a result
of being involved in AM clinics and reported job satisfac-
tion. The only area where there was a lower level of con-
sensus was in relation to nurses being able to admit
patients to hospital: 9 (39%) indicated they could, 4
(17%) said they could not and 10 (43%) were unsure or
did not respond.
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Free text comments by urologists showed some wished
to extend nurse skills to enable them to carry out DRE
and TRUS-Bx investigations, but were aware that appropri-
ate training, knowledge and support would be needed.
DRE was the most frequently cited skill that nurses wanted
to acquire and current inability to do this was cited as a sig-
niﬁcant gap in current nurse-led AM practice.
Research nurses indicated that nurse-led AM had
enabled them to develop greater autonomy, particularly
with regard to frequency of PSA testing and how patient
appointments were organised. Despite the protocol
allowing nurses to initiate testing, ﬁve nurses commen-
ted that they continued to make decisions about testing
in consultation with the urologist; some variation in
nurses initiating tests or hospital admission was attribu-
ted to local hospital trust policy. Some potential stressors
were identiﬁed, arising from lack of training or support
to carry out extended duties, but these were few in
number and could be countered by good support from
urologists. Nurses believed that AM was popular with
patients who informed them that they valued the con-
tinuity of care, accessibility and availability of staff. They
considered that the high percentage of men continuing
in AM was evidence of this.
DISCUSSION
Description of main findings
The ProtecT trial developed a model of nurse-led AM
for men with localised PCa that was acceptable to men,
urologists and nurses within the trial and of interest
outside it. Urologists believed that nurse-led AM had
enabled high-quality care to be delivered in a way that
simultaneously reduced the burden on urologist clinics
and brought patient beneﬁts. Nurses believed nurse-led
AM enabled them to increase their autonomy and
develop professionally, while providing a high-quality,
ﬂexible service to patients. Nurses valued good commu-
nication with urologists and used this to support their
practice even when they had autonomy to act (eg, in ini-
tiating tests). Patients within the ProtecT trial were very
positive about nurse-led care because it allowed ﬂexibil-
ity about the frequency and location of PSA blood tests
and appointments to discuss PSA results, and was per-
ceived to offer care that was more holistic, more access-
ible and had greater continuity than could be achieved
through the urologist-led model. Patients outside the
ProtecT trial perceived nurse-led care to be acceptable
and desirable given the imperative to use NHS resources
cost-effectively, and on condition that there were clear
lines of communication between nurses and urologists.
Small numbers of men receiving consultant-led care
outside ProtecT (3/20) expressed a preference for care
from the urologist; a similar number receiving nurse-led
care within ProtecT (2/22) expressed similar prefer-
ences at the time of ﬁrst interview (6–12 months post-
diagnosis), but these preferences had been replaced
with preference for nurse-led care by the time of the
third interview (5–6 years postdiagnosis). Urologists and
CNSs outside the ProtecT trial advocated a move
towards nurse-led AS/AM, believing it offered more efﬁ-
cient use of resources, a means to maintain and improve
the quality and consistency of care and was a natural
extension of existing nurse-led practice in monitoring
men who had received radical treatments. Nurses and
urologists highlighted the need for a clear protocol to
be in place, for clear lines of communication to exist
between nurses and urologists, and for nurses to be
given the appropriate skills, knowledge and support to
meet the demands of the role. Where tasks such as DRE
were not yet undertaken by nurses, urologists and nurses
wanted to expand their practice to include DRE as part
of routine care, but were aware that training and
support was required for them to do so.
Limitations of study
This research did not attempt to evaluate the clinical
effectiveness of the ProtecT nurse-led AM care model;
publication of the ProtecT trial ﬁndings is due in 2016.
The ProtecT AM nurse-led care was developed and eval-
uated within the ProtecT RCT, with support from
National Institute for Health Research (NIHR) for
research nurses to undertake follow-up and participate
in national meetings, site monitoring and training.
There was a stable workload in each trial centre once
recruitment had ceased, whereas in routine clinics the
number of men will continue to increase, potentially
requiring streamlining of the protocol over time.
The ProtecT RCT provided a framework to develop a
consistent protocol with application and evaluation in
nine UK cities. The protocol is clearly structured but ﬂex-
ible enough to encompass the particular model of AS/
AM that urologists wish to follow. There will be continued
pressure on urologist-led AS care as numbers of men
receiving PSA tests continue to increase following the
introduction of the latest NICE guidance.1 The ProtecT
protocol would enable more men to be monitored by
expanding the role of CNSs and with further integration
with primary care. Although the ProtecT model of
nurse-led AM allowed for PSA testing at GP surgeries, this
study did not investigate GPs perceptions of nurse-led
care or GPs views on nurse-led shared care delivered via
GP surgeries; further evaluation is required to identify
implications of greater integration with the primary care
setting and the challenges of a shared care protocol.
Although urologists, nurses and patients believed
nurse-led clinics were and would be cost-effective, this
requires evaluation; nurse-led recruitment was cost-
effective.20 The ProtecT trial employed an IT system that
ﬂagged men and produced reports to guide timing of
follow-up; routine clinics would beneﬁt from compar-
able IT support. There was some variation in clinical
practice by centre in terms of what activity the urologist
and nurse took responsibility for, hence variation in
urologist/nurse responses to questionnaires, particularly
in relation to tests initiated out by nurses.
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Relationship of findings to existing literature
Previous research has demonstrated the acceptability to
patients of nurse-led care for cancer survivors generally13
as well as PCa survivors following radical treatments in
particular.14 16 Nurse-led care has also been evaluated
for PCa diagnosis26 27 with positive ﬁndings regarding
patient satisfaction. This study described the develop-
ment of a model of nurse-led care for men with low-risk
or intermediate-risk PCa and evaluated its acceptability
to patients, clinicians and nurses, sampled to include
experiences of both urologist-led and nurse-led care.
Much previous work evaluating nurse-led care for PCa
has focused on follow-up either immediately postdiagno-
sis14 or postradical treatment;17 this study included
experiences of patients and staff involved in AS/AM for
up to 13 years.10 Previous research highlighted the need
for clearly deﬁned levels of responsibility and triggers
for onward referral;17 this study conﬁrmed these ﬁnd-
ings. Previous research speciﬁcally evaluating nurse-led
care for monitoring men with PCa delivered care exclu-
sively via telephone,14 with face-to-face and telephone
groups giving comparable ratings for general satisfaction
and professional care, and men receiving telephone-led
care having a shorter waiting time and lower scores for
depth of relationship and perceived time with the
nurse.14 In the ProtecT trial, there were high levels of
satisfaction with nurse-led care which facilitated care tai-
lored to the individual. This tailoring of care may have
countered some of the loss of satisfaction associated with
exclusively telephone follow-up.
Implications of study for policymakers, clinicians and
nurses, and future research
This study demonstrated that nurse-led care had the
approval of patients, urologists and nurses inside and
outside the ProtecT trial. Reduction of routine tasks by
consultants would suggest likely cost-effectiveness if urol-
ogists move to more specialised tasks. Concerns about
the psychological implications of AS/AM are sometimes
expressed28 and although evidence indicates patients
undergoing AS/AM report good quality of life, more
data are needed on longer follow-up.29 Accurate clinical
information is important in order to inform the patient
about the current status of their PCa, but men in the
interview study appreciated the holistic care and interest
in their individual needs, circumstances, beliefs and
values provided by nurses, backed by specialist urologists.
The model of nurse-led care allowed considerable ﬂexi-
bility in tailoring how, where and how often PSA tests
were carried out and this ﬂexibility was highly valued by
ProtecT trial patients. Further research will be required
to establish whether this degree of ﬂexibility is
cost-effective.
Nurses will need to be trained to take on the add-
itional responsibility and skills required for nurse-led
AS/AM. The opportunity to run nurse-led clinics in par-
allel with urologists was highly valued by nurses and urol-
ogists; further work is needed to establish how best to
build these into clinical practice and whether such paral-
lel clinics are required during nurse skills acquisition or
are of value more generally. Willingness to take on the
task of DRE was identiﬁed as a prerequisite for efﬁcient
nurse-led practice and could lead to less reliance on
urologist input.
The ﬁndings from this preliminary evaluation offer an
opportunity for the ProtecT AM model of care to be
developed further. Current NICE guidelines are based
on expert consensus in relation to monitoring men with
localised PCa,1 and much further research is required to
determine safe and accurate triggers for disease review
or the inclusion of repeat MRI/bone scans or biopsies.6
Further research is also needed to identify changes to
the protocol when the option of radical treatment is no
longer required or appropriate.
CONCLUSION
This study showed that the ProtecT trial nurse-led AM for
men with localised PCa was acceptable to patients, urolo-
gists and nurses because of the quality and continuity of
care it delivered and perceptions of cost-effectiveness.
Nurse-led care requires a protocol, effective communica-
tion between nurses and urologists and for the skill mix/
knowledge of nurses to develop in line with demands of
role. Nurse-led care has the potential to enable more
cost-effective use of resources for routine follow-up of
men with PCa following AS/AM.
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